WebWire
Global prescriptions for GLP‑1 medications such as semaglutide and tirzepatide are on pace to exceed $50 billion annually, yet up to 30 percent of patients miss or delay at least one weekly dose in the first three months, eroding clinical outcomes and driving costly drug waste. GLP‑1 Tracker (“GLP-1 Tracker”) enters the market today with a single goal: convert those high‑stakes injections into a seRead the full story at https://www.webwire.com/ViewPressRel.asp?aId=338825…
Read More
Neuromorph Systems Launches Morphētype a Revolutionary AI Writing Studio to Redefine Drafting and Editing Experience
Camellia Mongold
06:22
Global prescriptions for GLP‑1 medications such as semaglutide and tirzepatide are on pace to exceed $50 billion annually, yet up to 30 percent of patients miss or delay at least one weekly dose in the first three months, eroding clinical outcomes and driving costly drug waste. GLP‑1 Tracker (“GLP-1 Tracker”) enters the market today with a single goal:
